U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365150) titled 'Precision Use of TXA in Intracerebral Hemorrhage' on Jan. 02.
Brief Summary: Primary Intracerebral hemorrhage (ICH) is a severe and disabling disease. The hematoma will expand within the first few hours, which contributes to increasing brain injury and worsening neurological prognosis. Hence, one of ICH's main acute therapeutic strategies is to reduce hematoma expansion (HE) with hemostatic agents like tranexamic acid (TXA) or recombinant factor VIIa. However, although most HE trials have demonstrated that treatment attenuated HE, they have largely been unable to demonstrate therapeutic benefit in improving functional outcomes. The ...